Viatris Stock News

The generic drug manufacturer recently rewarded shareholders with a massive dividend hike.

This drugmaker might appeal to certain types of investors.

These two dividend-paying pharma stocks ought to be top performers in 2022.

In the latest trading session, Viatris (VTRS) closed at $14.36, marking a -1.17% move from the previous day.

The recent market sell-off has created even better bargains across value stocks. I highlight 2 stocks that provide good diversification and value.

All three of these stocks share a key attribute: resiliency.

Viatris Inc''s (NASDAQ: VTRS ) Mylan will pull one batch of non-interchangeable Semglee, also known as insulin glargine injection. The Company cited the risk of the label is missing on some prefilled pens contained inside labeled cartons of the drug. The recall doesn''t cover Viatris'' recently launched interchangeable Semglee biosimilars , which come in Full story available on Benzinga.com

Viatris Inc's (NASDAQ: VTRS) Mylan will pull one batch of non-interchangeable Semglee, also known as insulin glargine injection.  The Company cited the risk of the label is missing on some prefilled

Increasing real rates can hurt stocks in several ways, but so-called quality value stocks can thrive.

Viatris: Cheap Stock, Solid Dividend Yield, And Impressive Free Cash Flow

In the latest trading session, Viatris (VTRS) closed at $15.22, marking a +1.33% move from the previous day.

The company, formed by the merger of Mylan and the Upjohn division of Pfizer, has underwhelmed investors.

Viatris appears to be trading in bargain-basement territory at present. It has demonstrated stable business performance, and the biosimilars pipeline and cost synergies could be catalysts for 2022.